Navigation Links
FDA Panel Backs Stronger Warning for Tamiflu
Date:11/27/2007

Advisers say current labeling doesn't reflect reports of bizarre behaviors and sudden deaths

TUESDAY, Nov. 27 (HealthDay News) -- A U.S. Food and Drug Administration advisory panel recommended Tuesday that the prescription flu drug Tamiflu (oseltamivir) should have a strengthened warning label to reflect reports of bizarre behaviors and deaths among children.

The FDA's Pediatric Advisory Committee, in a 9-5 vote, said that drug maker Roche Holding AG should change its current prescribing information because it doesn't adequately explain side effects reported by hundreds of patients in Japan and the United States, according to Bloomberg News.

The drug's label mentions reports of delirium and self-injury, primarily among children in Japan, but the advisory panel said the language should state that several patients died as a result of these abnormal behaviors, the Associated Press reported.

In addition, the panel recommended that labeling for the flu drug Relenza, (zanamivir), should also reflect reports of bizarre behavior, according to Bloomberg.

The FDA is not obliged to follow its expert panels' recommendation, but it usually does. A safety review released Friday by the FDA's Division of Antiviral Products urged stronger label warnings for both drugs, including stricter monitoring of children taking these drugs.

According to the FDA safety review, there have been 596 reported cases of psychiatric behavior associated with Tamiflu use. Most of these cases happened among patients aged 21 or younger. The majority (75 percent) occurred in Japan.

Fifty-nine of the cases were classified as delirium with impulsive behavior and self-injury. Delirium, delusions, hallucinations or psychosis accounted for another 225 cases. In total, five children died "as a result of falls from windows or balconies or running into traffic," the safety review found, and three adults committed suicide. So far, there haven't been any such cases reported in the United States, according to the FDA.

The FDA safety review also reported that in cases involving Relenza, mostly in Japan, there have been 115 reports of "delirium with impulsive behavior and self-injury in which the patient expressed 'fear' and attempted to flee or expressed a desire to 'jump,'" the agency said. There were no deaths associated with Relenza.

During its meeting on Tuesday, the advisory panel said it was unclear whether the psychiatric problems are a side effect of Tamiflu or the flu itself, AP reported.

At the hearing, representatives of Roche told the panelists that the flu itself, not Tamiflu, caused the bizarre behaviors.

"We feel that the current U.S. prescribing information is an accurate assessment of the current data," Jonathan Solsky, Roche's director of drug-safety risk management, said according to Bloomberg.

In a statement released after the meeting, Roche reiterated its faith in the drug. "According to data analyzed from two U.S. claims databases of more than 150,000 patients, there is no increased risk for neuropsychiatric events in influenza patients treated with Tamiflu compared to untreated influenza patients," the statement said.

The FDA first began reviewing Tamiflu in 2005, and, since November 2006, the drug's label has had a warning focused on self-injury and delirium, advising that patients be monitored during treatment. In March, the Japanese Ministry of Health, Labor and Welfare limited Tamiflu use in patients aged 10 to 19 years old.

One expert believes a new warning is appropriate for Tamiflu. "The idea that there have been 596 neuropsychiatric events is a reason for the FDA to put a strong warning on the label," said Dr. Marc Siegel, a clinical associate professor of medicine at New York University School of Medicine in New York City.

But he is also concerned that the public might overreact.

"I am not a fan of replacing fear of a disease with fear of the treatment for the disease," said Siegel, speaking before the advisory panel met. "You don't need to go from one panic to another."

Tamiflu is overused, however, Siegel added. "It's supposed to be used in a very narrow window, and I am not surprised that there have been psychiatric side effects related to this drug," he said. "Maybe the new warning will lead to less overuse."

Tamiflu is approved both as a preventive and a treatment for flu for adults and children aged 1 year and older.

Relenza is approved as both a flu preventive and a treatment in adults and children aged 5 years old and older.

GlaxoSmithKline, the British maker of Relenza, doesn't believe the label needs changing. "The review and analysis of all the information available in this safety summary of neuropsychiatric events does not implicate or indicate a significant causal role of zanamivir. Therefore, no revisions are warranted for the U.S. Prescribing Information and the FDA-approved Patient Labeling for Relenza," the company told the FDA.

More information

For more on flu, visit the U.S. Centers for Disease Control and Prevention.



SOURCES: Marc Siegel, M.D., clinical associate professor, medicine, New York University School of Medicine, New York City; Pediatric Safety Update for Tamiflu, Division of Antiviral Products, U.S. Food and Drug Administration; statements, GlaxoSmithKline and Hoffmann-La Roche Inc.; Bloomberg news; Associated Press


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
2. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
3. Patient Safety Authority Board of Directors Names Infection Advisory Panel
4. Partners Rx Chief Pharmacy Officer, Richard Bullard on Panel Discussion at the Fall 2007 Managed Markets Summit (MMS) in Phoenix, AZ.
5. Billians HealthDATA GM Speaking on Dreamforce 07 Panel
6. FDA Panel Recommends Approval of SyntheMeds REPEL-CV(R) Adhesion Barrier for Pediatric Patients
7. Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers
8. Health Courts Critic to be Featured Speaker at Wyoming Patient Safety Panel
9. FDA Panel Mulls Ban on Kids Cold Medicines
10. FDA Panel Weighs Ban on Kids Cold Medicines
11. FDA Panel Recommends Ban on Cold Medicines for Kids
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Panel Backs Stronger Warning for Tamiflu
(Date:2/11/2016)... ... February 11, 2016 , ... From March ... Academy of Dermatology Annual Meeting at the Walter E. Washington Convention Center in ... for both the condition of hyperhidrosis (excessive sweating) and its treatment options. Specifically, ...
(Date:2/11/2016)... ... February 11, 2016 , ... Husted Kicking has completed its Third ... February 6th & 7th, 2016 according to kicking coach Michael Husted. , “This event ... the NFL’s combine in Indianapolis,” says Husted. “The NFL uses a third party organization ...
(Date:2/11/2016)... ... February 11, 2016 , ... The book, “Computers Should ... services, what questions to ask your IT consultant before signing a contract and how ... computer network. , “With companies relying heavily on e-mail and technology, it’s more important ...
(Date:2/11/2016)... ... February 11, 2016 , ... As part of their 2015 end of ... Round Table Foundation (MDRTF), has gifted $10,000 to University of Chicago to support ovarian ... Billy Cundiff. , “We are honored to support a promising young investigator from Dr. ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... as the World Molecular Imaging Congress (WMIC), will be held in New York ... meeting is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... F ast access to ... at the point of need   ... and services, has launched a ClinicalKey mobile app that enables ... Elsevier designed the mobile app to allow users to select access to ... Android and iOS formats for mobile phone and tablet. ...
(Date:2/11/2016)... , Feb. 11, 2016 Scientists ... cell-isolation method that opens the door to genetic ... now have been impossible to isolate with 100 ... isolate specific tumor types in various stages of ... variants of these cells that are clinically relevant, ...
(Date:2/11/2016)... , Feb. 11, 2016  NanoViricides, Inc. ... it has entered into an agreement with the ... nanoviricides® drug candidates in standard animal models of ... , Research Director. Dr. Romanowski has extensive experience ... --> Eric Romanowski , Research ...
Breaking Medicine Technology: